Articles tagged with Cancer Patients
Research in mice suggests that melanomas and other cancers driven by BRAF V600E mutation will grow faster in response to a high-fat diet. Lipid-lowering agents such as statins can slow tumor growth, even on normal diets. The findings highlight the potential of precision diets tailored to individual patients' cancer mutations.
Scientists developed a biosensor that can detect cancer proteins in serum samples, allowing for early detection of tumors. The method is faster and more accurate than traditional methods, with a 440-fold higher sensitivity.
A University of North Carolina researcher argues that integrating patient-reported symptoms into clinical practice can improve patient outcomes. Despite demonstrated benefits, cost and technology barriers prevent the widespread adoption of electronic symptom reporting.
Researchers have discovered that Dab2 controls a population of fat stem cells that slowly disappears with maturity. This finding may reinforce the importance of steering children away from high-fat diets and lead to new pharmaceutical strategies to combat childhood obesity.
A landmark study reveals that men with a family history of prostate cancer and the BRCA2 gene fault have a more aggressive form of prostate cancer. The study shows that these cancers are genetically similar to advanced cancers, explaining why BRCA2 patients have poor outcomes.
A Mayo Clinic study finds that vaginal microbes are distinct in women with endometrial cancer compared to those without the disease. Researchers hope to use vaginal swabs as an early screening tool and investigate the role of the microbiome in preventing endometrial cancer.
A recent study published in JAMA Oncology suggests that chemotherapy can still benefit patients with non-small-cell lung cancer who recover slowly from surgery. The study found that delaying chemotherapy by up to four months did not increase the risk of death and may even lower it compared to earlier treatment.
A study by Yale researchers found that older lung cancer patients can spend an average of one in three days interacting with the healthcare system within the first 60 days after surgery or radiation therapy. Patients with a higher number of medical conditions treated with surgery had the most post-treatment burdens.
Researchers have identified a gene mutation driving the formation of metaplastic breast cancer, a subtype of triple negative breast cancer. A therapeutic compound has been validated to slow tumor growth and increase chemotherapy efficacy.
A study published in Journal of Clinical Oncology found that new therapies for non-small cell lung cancer resulted in a median 1.5-month survival increase, but this gain was largely offset by higher outpatient spending due to the expensive medications.
A new HER2-targeted dendritic cell vaccine has shown promising results in a clinical trial, stimulating an immune response in 80% of patients and inducing regression of early-stage breast tumors. The vaccine was well-tolerated and effective in both invasive and non-invasive disease settings.
A new oral drug, selumetinib, has shown significant tumor shrinkage in children with neurofibromatosis type 1 (NF1) and plexiform neurofibromas. Most patients experienced partial responses, with tumor growth stopping in over 70% of cases.
A recent study has identified more than 2,000 genetic mutations in tissue samples of esophageal tumors, revealing the complexity of cancer cells within individual tumors. The findings demonstrate that different areas of a tumor have unique genetic patterns, making it difficult to target a specific genetic defect.
A major clinical trial has found that adding bortezomib to a standard two-drug regimen significantly prolongs the time before multiple myeloma cancer returns, giving patients about another year of remission. The study also shows that patients who receive this combination therapy live an average of six years after initial treatment.
Researchers developed iCAGES, a computational tool that integrates whole genome-based approach to identify individual cancer driver genes and select treatment options. The tool was found to be superior in predicting cancer drivers and identifying beneficial treatments compared to other computational tools.
Researchers developed a dual strategy combining biomimetic beads and anti-PD1 therapy to boost killer T cell immunity against skin cancer. The combination technique increased T cell activation by 35% compared to artificial beads alone and 72% compared to anti-PD1 alone.
Scientists have discovered a potential biomarker, GHRH-R, for gastric cancer, which can aid in earlier diagnoses and better staging. The team also found that the GHRH-R antagonist MIA-602 inhibited gastric cancer growth in cell lines and human xenografts.
Regular NSAID use associated with a 66% increased risk of dying from endometrial cancer, particularly among those who had used NSAIDs for over 10 years. However, the association did not apply to more aggressive Type 2 cancers.
Researchers found a strong correlation between circulating tumor DNA (ctDNA) and poor outcomes in pancreatic cancer patients. ctDNA levels were associated with disease stage, grade of differentiation, and overall survival. The study suggests that detecting ctDNA could help subclassify cancers and manage treatment.
A genetic biomarker, rs28714259, identifies women with breast cancer at increased risk for anthracycline-induced congestive heart failure. The marker is associated with low ventricular ejection fraction and may help oncologists provide more precise predictions of treatment risks.
A study found that cancer patients spend a significant portion of their household income on treatment, transport, and childcare. The economic burden is often referred to as the 'financial toxicity' of cancer.
A Malaysian study found that four in five cancer survivors suffer from anxiety and depression a year after diagnosis. The study also highlighted the importance of addressing quality of life for cancer patients beyond clinical outcomes.
A routine blood test can predict how long cancer patients in palliative care will survive, researchers report. The Six Adaptable Prognostic models use three laboratory measurements to estimate death within 1-6 months, allowing physicians to re-evaluate prognosis at any time point.
Researchers present first data on rare sarcomas in Asian patients, showing poor overall survival rates. Chemotherapy improves survival in advanced cases, but treatment rates remain low, with physician-related factors possibly at play.
Researchers have created a unique model of prostate cancer biology using patient tissue, allowing them to study the differences between normal and cancerous cells. The breakthrough uses conditional reprogramming, a laboratory technique that enables continuous growth of healthy and cancer cells indefinitely.
A statewide colorectal cancer screening study found that 16% of patients diagnosed under age 50 have an inherited genetic mutation increasing their cancer risk. The study identified a broad spectrum of mutations in early-onset colon cancer patients, including those linked to breast cancer risk.
A study found that patients with oropharyngeal cancer who recur have higher levels of antibodies for proteins E6 and E7, which can detect recurrence before it's diagnosed. This biomarker could provide an early window for treatment.
A new study comparing two genetic sequencing tests found that results can differ significantly in the same patients, with only 22% of detected alterations matching between platforms. The findings have significant clinical implications, highlighting the need for more detailed comparisons of test results across larger patient populations.
A University of Alberta study found that proton pump inhibitors (PPIs) decrease capecitabine's effectiveness in gastric cancer treatment, reducing progression-free survival by over a month and overall survival by two months. PPIs can also affect colorectal cancer treatment efficacy.
A study of 450 patients found 72 with 75 unique gene mutations, affecting 16 percent of younger-onset CRC cases, suggesting genetic counseling and multigene panel testing for early-onset patients
A new study found that socially isolated breast cancer survivors had a 40% higher risk of recurrence, a 60% higher risk of dying from breast cancer, and a 70% higher risk of dying from any cause. Women with larger social networks experienced better outcomes.
A new study published in The American Journal of Pathology found that over 90% of bladder cancers lack the enzyme argininosuccinate synthetase 1, making them susceptible to arginine-degrading therapy. This approach has shown promising results in treating bladder cancer with low ASS1 expression.
A study presented at EuroEcho-Imaging 2016 found that chemotherapy caused heart damage in cancer patients with diabetes, leading to a higher risk of heart failure. The researchers also discovered that patients with diabetes experienced a significant decrease in global longitudinal strain, an early predictor of heart failure.
Research reveals that 20-40% of multiple myeloma patients have a defective ribosome, leading to a poorer prognosis but better response to Bortezomib treatment. The discovery has the potential to improve therapy selection for these patients.
A new Penn study sheds light on racial disparities in cancer-causing genetic mutations, finding differences in mutation patterns between African American and Caucasian women. The research suggests biological differences and potentially different genetic factors may be at play, guiding targeted care for at-risk patients.
A large Canadian clinical trial found that a new treatment strategy for locally advanced squamous cell head and neck cancer did not show better results compared to the current standard of care. The study provided valuable data on quality of life and biospecimens from 320 patients, informing future research.
A lack of psychiatric healthcare providers in rural areas is leaving patients without access to necessary treatment options, exacerbating the impact of untreated mental illness. The OHSU Knight Cancer Institute is working to address this issue through innovative approaches to cancer care and mental health support.
A new study published in BMC Public Health found that people who are more body vigilant are more likely to seek medical help. Researchers from the University of Surrey discovered that nearly half of those diagnosed with cancer were at an advanced stage, highlighting the importance of early diagnosis.
French researchers report harmonization study on PD-L1 immunohistochemistry testing in NSCLC. Durvalumab shows clinical activity and well-tolerability in heavily-pretreated patients with NSCLC. Patients receiving pembrolizumab report better quality of life than those on chemotherapy.
Patients with longer delays were more likely to receive palliative treatment, while early diagnosis and treatment improve cancer outcomes. The study found that patients and primary care physicians contributed significant delays, highlighting the need for increased patient awareness about symptoms and screening.
Supportive care, including pain relief and medication to prevent side effects, remains insufficient for many cancer patients, especially those on government-funded schemes in India. This can lead to delayed treatment cycles and poor quality of life. Researchers emphasize the need for better policies and access to effective treatments.
Researchers discovered two genetic mutations in the CCND1 and CCND2 genes in a subset of acute myeloid leukemia patients. These mutations were found in 15% of patients with t(8;21) AML, making them a potential target for new therapies.
A personalized cancer vaccine significantly improved outcomes for patients with acute myeloid leukemia (AML) in a clinical trial, showing protection from relapse in most patients and minimal side effects. The vaccine stimulated powerful immune responses against AML cells, using the body's own defense systems to fight cancer.
A new blood test can detect Merkel cell carcinoma (MCC) earlier and more effectively than traditional imaging studies. The test uses an immune system marker to identify patients at high risk of recurrence, allowing for earlier treatment with immune therapy.
A study led by Dr. Steven A. Rosenberg identified a method to target the cancer-causing protein produced by a mutant form of the KRAS gene, leading to cancer regression in a patient with colorectal cancer. The treatment involved infusing tumor-infiltrating lymphocytes into the patient, which recognized and attacked the mutated cells.
Researchers from IASLC present significant findings on osimertinib reducing disease progression by 70% in patients with non-small cell lung cancer. Additionally, studies demonstrate improved progression-free survival and reduced side effects for icotinib-treated patients with brain metastases.
The phase 2 portion of the ZUMA-1 study using KTE-C19 CAR-T therapy achieved complete remission in all 6 patients with refractory primary mediastinal B-cell lymphoma or transformed follicular lymphoma, with manageable toxicities. The treatment was well-tolerated, with grade 3 adverse events occurring in 17% of patients.
A new study found that psychosocial risk factors, such as depression and anxiety, are associated with higher readmission rates and longer hospital stays among blood cancer patients. The study suggests that upfront assessment of patients' ability to cope and social support can improve recovery post treatment.
Researchers found that children with Down syndrome did not experience higher rates of relapse or treatment-related mortality compared to other children treated on the same protocols. However, they suffered more treatment-related mucositis and infections. The study suggests that supportive care can help mitigate these complications.
A study of over 290,000 adults found that even low-intensity smokers had a significantly higher risk of earlier death than never smokers. The risk was particularly strong for lung cancer mortality, with low-intensity smokers experiencing nearly 9 times the risk of dying from lung cancer.
A study from Dana-Farber Cancer Institute found that 30% of lymphoma patients with autologous transplants carry genetic mutations increasing their risk of developing second blood cancers and dying from other causes. The most commonly mutated gene was PPM1D, associated with an abnormal condition called CHIP.
A study by The University of Texas MD Anderson Cancer Center found pre-leukemic mutations can predict the development of therapy-related myeloid neoplasms (t-MNs), a leukemia with poor prognosis. Patients with these mutations are at higher risk, and detecting them earlier could help prevent or treat t-MNs.
The phase 3 ECOG-ACRIN E2905 Intergroup Study found that lenalidomide plus epoetin alpha resulted in improved major erythroid response rates and a similar toxicity profile compared to lenalidomide alone. This combination therapy showed significant benefits for patients with lower-risk, erythropoietin-refractory MDS.
Patients with a history of cancer who experience severe heart attacks have a three times higher risk of noncardiac death but not higher cardiac death rates. They also face increased risks of cardiogenic shock and need more intensive treatment.
A 69-year-old Vietnam war veteran was diagnosed with pleomorphic liposarcoma, a rare type of cancer, after exposure to Agent Orange during his service. The patient's cancer has a high rate of local recurrence and ability to spread to other parts of the body, making early detection crucial.
A team of researchers has established a molecular link between Fanconi anemia and the PTEN gene, strongly associated with uterine, prostate, and brain cancer. The discovery improves understanding of Fanconi anemia and could lead to improved treatment outcomes for some cancer patients.
A study published in Cancer Epidemiology, Biomarkers & Prevention found that alcohol intake is associated with a higher risk of invasive melanoma, especially among individuals who consume more than 20 grams of alcohol per day. White wine was the most clearly associated with increased risk.
A phase I trial of LY3039478 showed the drug's ability to inhibit Notch signalling pathway in patients with various advanced cancers. The treatment resulted in tumour shrinkage and disease stabilisation, particularly in rare cancers like adenoid cystic carcinoma.
A four-week prehabilitation program has shown promising results in preparing cancer patients for surgery by improving their physical fitness and reducing recovery time. The study involved 116 colorectal cancer patients who underwent the program before undergoing surgery.
A clinical trial led by NYU Langone Health found that psilocybin significantly reduces mental anguish in distressed cancer patients for months. The study showed that one-time treatment with psilocybin quickly brought relief from distress that then lasted for over six months in 80% of the participants.